CA

Peter Rothbart

This inventor holds 15 USPTO granted patents. Top assignees: L.a.m. Pharmaceutical Corporation, L.a.m. Pharmaceuticals LLC, Rdn Therapeutics Inc.. Active years: 1998-2004.


% Patents Active = 93.3

Average Co-Inventor Count = 3.0

ph-index = 8

Forward Citations = 312(Granted Patents)


Company Filing History:


Years Active: 1998-2004

Loading Chart...
15 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Peter Rothbart

Introduction

Peter Rothbart is a notable inventor based in California, recognized for his significant contributions to the field of pharmaceutical innovations. With a total of 15 patents to his name, Rothbart has made strides in developing topical drug preparations that address various medical conditions.

Latest Patents

Among his latest patents, Rothbart has developed topical gelled compositions that comprise an optional drug dispersed within a polymer matrix. These compositions are designed for effective treatment methods. Additionally, he has created drug preparations aimed at treating sexual dysfunction, which include a drug that causes vasodilation and optionally prostaglandin E, also dispersed within a polymer matrix. These innovative treatments cater to both male and female sexual dysfunction.

Career Highlights

Throughout his career, Rothbart has worked with prominent companies such as L.A.M. Pharmaceutical Corporation and L.A.M. Pharmaceuticals LLC. His work in these organizations has allowed him to further his research and development in pharmaceutical formulations.

Collaborations

Rothbart has collaborated with notable professionals in the field, including Alan Drizen and Gary M. Nath. These partnerships have contributed to the advancement of his innovative projects.

Conclusion

Peter Rothbart's contributions to pharmaceutical innovations through his patents and collaborations highlight his role as a significant figure in the industry. His work continues to impact the development of effective treatments for various medical conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…